ArticleChina CDC weekly2026
Effectiveness of One- and Two-Dose Varicella Vaccination Among Children and Adolescents Aged 0-18 Years - Chaoyang District, Beijing, China, 2007-2025.
Article in China CDC weekly, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Varicella is a highly contagious respiratory disease caused by the varicella-zoster virus that predominantly affects children and is prone to outbreaks in congregate settings. This study evaluated the effectiveness of varicella vaccination among children and adolescents aged 0-18 years in Chaoyang District and examined factors associated with infection risk. Methods: A retrospective cohort study was conducted among 551,980 children and adolescents born between 2007 and 2025 using varicella surveillance data from the Chaoyang District Center for Disease Control and Prevention. Incidence rates were calculated, and vaccine effectiveness was estimated using Cox proportional hazards models. Results: Among the 551,980 participants, 9,170 varicella cases were identified. The incidence rate was 20.79 per 1,000 person-years (PY) in the unvaccinated group, 2.28 per 1,000 PY in the one-dose group, and 0.34 per 1,000 PY in the two-dose group. Increasing vaccine dose number was significantly associated with a lower risk of infection. The cumulative incidence of varicella was lowest and most stable in the two-dose group during follow-up. Vaccine effectiveness (VE) was 96.8% [95% confidence interval ( Conclusion: Two doses of varicella vaccine provided strong protection against varicella. These findings support efforts to increase two-dose vaccination coverage and optimize varicella immunization schedules.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.